| Q-Line Biotech Limited | ||||||
| Ratings reaffirmed at 'Crisil BBB+/Stable/Crisil A2' | ||||||
| Rating Action | ||||||
| ||||||
| Note: None of the Directors on Crisil Ratings Limited’s Board are members of rating committee and thus do not participate in discussion or assignment of any ratings. The Board of Directors also does not discuss any ratings at its meetings. | ||||||
| 1 crore = 10 million | ||||||
| Refer to Annexure for Details of Instruments & Bank Facilities |
Detailed Rationale Crisil Ratings has reaffirmed its ‘Crisil BBB+/Stable/Crisil A2' ratings on the bank facilities of Q-Line Biotech Limited (QLBL; Formerly known as Q-Line Biotech Private Limited; part of the Poct group).
The ratings continue to reflect the group’s established market position, its diversified revenue profile and strong financial risk profile. These strengths are partially offset by working capital intensive nature of operations. |
Analytical Approach Crisil Ratings has combined the business and financial risk profiles of Poct Services (PS), QLBL and Heidelco Medicore Pvt Ltd (HMPL). This is because all these entities, collectively referred to as the Poct group, are managed by the same promoters and have strong business and financial linkages.
Please refer to Annexure - List of Entities Consolidated, which captures the list of entities considered and their analytical treatment of consolidation. |
Key Rating Drivers & Detailed Description Strengths: Established market position: The group's market position has been significantly improved backed by the promoters over two decades of experience in the medical equipment trading industry and their strong relationships with key suppliers and customers. This, combined with the group’s long-standing industry presence, strategic tie-ups with government and private entities, and regular product mix expansions - including a growing proportion of reagents and critical care equipment - has further strengthened its market position. As a result, the group has achieved sustained revenue growth, with a compound annual growth rate (CAGR) of around 15% over the past three years, culminating in estimated revenues of approximately Rs 780 crore for fiscal 2025. The group is poised for further expansion, with discussions underway with reputable new customers to establish a Contract Development and Manufacturing Organization (CDMO) partnership at its new Lucknow facility and plans to enter new geographies, solidifying its market position in the coming years. Driving this growth will be increased penetration into critical care equipment, medical devices, and pathological equipment, as well as steady demand for reagents, ultimately supporting the group's business growth over the medium term.
Diversified revenue profile: The group's diversified revenue streams, comprising reagents, equipment, and laboratory services, have helped maintain its market position despite challenges. This diversification insulates the group against any market volatility, as the group offset declining sales of one segment by increasing contribution from other segments, thereby sustaining its topline. Going forward, with demand for critical care instruments stabilizing, the group's revenue is expected to be driven by a surge in sales from critical care, steady demand in reagent segment and growing demand for laboratory instruments.
Strong financial risk profile: The group's debt-funded capital expenditures over the past few years have driven the setup of manufacturing units for critical care instruments, consumables, and medical devices. Resultantly, debt has increased for capital expenditure and working capital requirements due to expanding operations in fiscal 2024 and 2025, outpacing previous years. However, significant reserve accretion has yielded a strong capital structure, with a net worth of Rs. 372 crores and a gearing of 1.1 times as of March 31, 2025. Going forward, the net worth is expected to reach Rs. 450–475 crores, with gearing below 1 time in fiscal 2026 and onwards. The group’s financial health is further bolstered by healthy operating margins and efficient debtor realization, resulting in strong debt protection metrics — including interest coverage and net cash accrual to adjusted debt ratios of 5.8 times and 0.24 times, respectively, in fiscal 2025. With steady reserve accretion and a low dividend payout, the financial risk profile is poised to improve over the medium term.
Weaknesses: Working capital intensive operations: The group's operations are working capital-intensive, with a gross current asset (GCA) cycle of approximately 360 days as of March 31, 2025, driven by the need to maintain a large inventory to minimize turnaround time for high-value customers and meet business requirements. Inventory days stood at around 135 days as of March 31, 2025. The group’s receivables are also high, ranging from 140-180 days, with an average of 175 days as of March 31, 2025, due to the prevalence of government organizations as counter parties, which often delay payments. As a result, the group's increasing working capital requirements have led to a growing dependence on bank debt, impacting its leverage position. While supplier credit support partially offsets this, efficient working capital management will be crucial to reducing bank debt dependence, improving the financial risk profile, and enhancing liquidity, making it a key rating sensitivity factor. |
Liquidity: Adequate The bank limit utilization has been moderately high, averaging around 83% over the past twelve months, as of June 2025. However, expected cash accruals of over Rs. 100–120 crore will be sufficient to cover term debt obligations of Rs. 15–20 crore over the medium term, providing a cushion for the group’s liquidity. The current ratio is healthy, at 1.7 times as of March 31, 2025, and is expected to remain so over the medium term. Although liquidity is partly constrained due to significant capital withdrawals from the group, the extent of these withdrawals is likely to decrease over the medium term. |
Outlook: Stable Crisil Ratings believes the Poct group will continue to benefit from its established market position and strong relationships with key customers and suppliers. |
Rating Sensitivity Factors Upward factors
Downward factors
|
About the Company Set up in 2008 as a partnership firm by Mr. Saurabh Garg and Ms. Amita Garg, PS is based in Lucknow, Uttar Pradesh. The firm trades reagents, diagnostic machines, and medical equipment, such as pathology equipment, consumables, and reagent diagnostic kits. It also offers laboratory services to government hospitals and medical colleges.
QLBL manufactures reagents and trades medical equipment. It sells its products through 150 distributors.
HMPL manufactures and trades critical care equipment and cardiology products. |
Key Financial Indicators- Standalone
|
Any other information: Not Applicable |
Note on complexity levels of the rated instrument: |
Annexure - Details of Instrument(s)
|
Annexure - List of Entities Consolidated
|
| Annexure - Rating History for last 3 Years | ||||||||||||||||||||||||||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||||||||||||||||||||||||||
| All amounts are in Rs.Cr. | ||||||||||||||||||||||||||||||||||||||||||||||||||||
| Annexure - Details of Bank Lenders & Facilities | ||||||||||||||||||||||||||||||||||||||||
|
Criteria Details
|